You are here: Home » Health » News
Business Standard

Zydus Cadila gets USFDA nod to market its cancer treatment injection

Drug firm Zydus Cadila said it has received final nod from USFDA to market its generic Doxorubicin Hydrochloride Liposome injection, used for treatment of certain types of cancer, in the US

Zydus Cadila | cancer treatment | USFDA

Press Trust of India  |  New Delhi 

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing

Drug firm on Friday said it has received final nod from the US health regulator to market its generic Doxorubicin Hydrochloride Liposome injection, used for treatment of certain types of cancer, in the American market.

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Doxorubicin Hydrochloride Liposome injection in the strengths of 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials, said in a statement.

This is the group's first approval for a complex injectable which has been developed in-house and will be manufactured at the group's facility, it added.

According to IQVIA, the US sales for Liposomal Doxorubicin injection were approximately USD 124 million (about Rs 910 crore) for the 12 months ending July 2020, said.

"This FDA approval of Liposomal Doxorubicin injection demonstrates our long-term commitment to drive growth through investment in complex generic products," Zydus Cadila MD Sharvil Patel said.

"Through this investment, we have created a diversified portfolio of complex abbreviated new drug applications (ANDAs). This portfolio provides continued opportunities to grow our US business in 2021 and beyond," he added.

Liposomal Doxorubicin is a chemotherapeutic agent that is used alone or with other treatments/medications to treat certain types of cancer such as ovarian cancer, AIDS-related Kaposi's sarcoma and multiple myeloma.

It works by slowing or stopping cancer cell growth, the statement said.

The group now has 300 approvals and has so far filed over 390 ANDAs since the commencement of its filing process, it added.

Shares of Cadila Healthcare, the listed entity of the group, closed 1.73 per cent higher at Rs369.95per scrip on the BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, September 11 2020. 16:41 IST